In this month’s episode of the "CURE Talks Cancer Podcast: Nursing Edition," we had the chance to talk with Betty Ferrell, FAACN, FCPN, MA, PhD, director of the Division of Nursing Research and Education at City of Hope, and discuss the important differences between palliative care and end of life care.
The FDA has approved acalabrutinib for the treatment of adult patients with CLL or SLL.
In a phase III trial of nivolumab/ipilimumab to treat patients with melanoma in the adjuvant setting results showed the drugs missed their coprimary end point.
New studies are showing the dawn of a new era in how cancer care teams will go about treating patients with small cell lung cancer with immunotherapy combinations.
The FDA accepts the application of a biosimilar of bevacizumab in the treatment of patients with NSCLC.
Immunotherapy as a frontline treatment for patients with advanced nonsquamous NSCLC is showing potential, but there is still additional testing that needs to be done.
Biosimilars are beginning to change the way oncology professionals treat patients with cancer, and this could help alleviate the financial burden of care.
Patients with cancer undergoing stem cell transplant are experiencing depression at higher rates than other cancer survivors, and special interventions are required to address their psychosocial needs.
The Food and Drug Administration granted accelerated approval to zanubrutinib for the treatment of relapsed and refractory mantle cell lymphoma.
Lung cancer treatments are advancing. With these changes come new complications and questions that nurses will have to address with their patients.
Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.
The FDA has granted a priority review to the combination treatment of nivolumab and ipilimumab to treat patients with advanced HCC.
The therapy is now approved for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.
Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.
Steps in orthopedic oncology are being made after the first-ever global perspective trial in its field completed patient accrual.
Several late-stage therapies, including targeted agents and immunotherapies, are being evaluated for patients with relapsed/refractory colorectal cancer (CRC) who have progressed on first- and second-line therapies.
New study results show that chemoimmunotherapy combination options provide an overall survival benefit to patients with stage IV nonsquamous NSCLC.
The FDA has approved the biosimilar pegfilgrastim for treatment to decrease the incidence of infection exhibited from febrile neutropenia.
Wnt emerges as an exciting and favorable pathway for the treatment of patients with CRC.
President Trump has announced he will be nominating Stephen M. Hahn, MD, FASTRO, to be the next commissioner of the FDA.
Patients with cancer are faced with chronic pain that nurses often cannot manage properly due to outdated restrictions and practices.
Any patient with cancer needs a caregiver through the treatment journey, but it's even more vital for patients with cancer undergoing the stem cell transplant process.
The FDA has granted an RMAT designation for an investigational CAR-T cell therapy used to treat patients with multiple myeloma.
Here are the top 5 Oncology Nursing News® stories for October 2019.
Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.
New therapeutic options are emerging for patients with Lung cancer positive for ALK or ROS1.
The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.
An update to the biologics license application of eflapegrastim has been resubmitted to the FDA to include chemo-induced neutropenia.
Following concerns over breast implant-associated cancer and illnesses, the Food and Drug Administration issued draft guidelines for additional labeling measures on devices.
